Is Scinai Immunotherapeutics Ltd. (SCNI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 77.1% / 30% | 72.6% / 30% | 8.0% / 30% | 15.2% / 5% | ✗ NOT HALAL |
| DJIM | 77.1% / 33% | 72.6% / 33% | 8.0% / 33% | 15.2% / 5% | ✗ NOT HALAL |
| MSCI | 15.5% / 33% | 14.6% / 33% | 1.6% / 33% | 15.2% / 5% | ✗ NOT HALAL |
| S&P | 77.1% / 33% | 72.6% / 33% | 8.0% / 33% | 15.2% / 5% | ✗ NOT HALAL |
| FTSE | 15.5% / 33% | 14.6% / 33% | 1.6% / 50% | 15.2% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -147.0% | |
| Operating Margin | -486.8% | |
| Net Margin | 448.4% | |
| Return on Equity (ROE) | 1792.0% | |
| Return on Assets (ROA) | -39.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$6M |
| Free Cash Flow | -$6M |
| Total Debt | $2M |
| Debt-to-Equity | 30.0 |
| Current Ratio | 0.7 |
| Total Assets | $13M |
Price & Trading
| Last Close | $0.60 |
| 50-Day MA | $0.82 |
| 200-Day MA | $1.31 |
| Avg Volume | 46K |
| Beta | 1.9 |
|
52-Week Range
$0.55
| |
About Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Scinai Immunotherapeutics Ltd. (SCNI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Scinai Immunotherapeutics Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Scinai Immunotherapeutics Ltd.'s debt ratio?
Scinai Immunotherapeutics Ltd.'s debt ratio is 77.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 15.5%.
What are Scinai Immunotherapeutics Ltd.'s key financial metrics?
Scinai Immunotherapeutics Ltd. has a market capitalization of $2M, trailing P/E ratio of 0.2, and revenue of $658,000. The company maintains a gross margin of -147.0% and a net margin of 448.4%. Return on equity stands at 1792.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.